{"eventGroups":[{"description":"Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":22,"seriousNumAffected":2,"seriousNumAtRisk":22,"title":"Lenalidomide"},{"description":"Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":16,"seriousNumAffected":2,"seriousNumAtRisk":16,"title":"Placebo"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":16,"numEvents":1}],"term":"Myocardial Infartion"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":16,"numEvents":1}],"term":"Musculoskeletal Pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":16,"numEvents":0}],"term":"Bleeding"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":16,"numEvents":0}],"term":"Ischemic Colitis"}]}